Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2019-08-14 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest increases adjusted EBIT by 12% to EUR 29.9 million
Earnings Release Classification · 100% confidence The document is a press release dated August 14, 2019, titled 'Biotest increases adjusted EBIT by 12% to EUR 29.9 million' and explicitly tagged with the keyword 'Half Year Results'. It provides detailed financial figures (sales revenues, EBIT, EBT) for the first half of the 2019 financial year, discusses operational progress (Biotest Next Level project), and provides an outlook for the full year. This content structure—a comprehensive summary of financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report. Furthermore, the document explicitly states, 'The half-year report can be downloaded from the company’s website...', indicating this text is the announcement/summary of that report, but given the depth of financial data provided, it functions as the primary release of the interim results, aligning best with the Interim / Quarterly Report (IR) definition, rather than just a brief RPA. The presence of detailed financial metrics for a half-year period confirms this classification over a simple Earnings Release (ER) which usually contains only key highlights. H1 2019
2019-08-14 English
Datum:14.08.2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halbjahresbericht 2019' (Half-Year Report 2019) for Biotest AG. It contains comprehensive financial data, including a balance sheet, income statement, cash flow analysis, and a detailed management report (Konzernzwischenlagebericht). As it covers a period shorter than a full fiscal year (first half of 2019) and provides substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2019
2019-08-14 German
Half-yearly financial report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR REPORT 2019 BIOTEST AG' and contains comprehensive financial statements, including a consolidated statement of income, financial position, cash flow, and management discussion and analysis for the six-month period ending June 30, 2019. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report. H2 2019
2019-08-14 English
Halbjahresfinanzbericht 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALBJAHRESBERICHT 2019 DER BIOTEST AG' (Half-Year Report 2019 of Biotest AG). It contains comprehensive financial statements, including a balance sheet, income statement, cash flow statement, and management discussion and analysis (Konzernzwischenlagebericht) for the period ending June 30, 2019. As it is a substantive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2019
2019-08-14 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2018 bis zum 31.12.2018
Notice of Dividend Amount Classification · 98% confidence The document is a formal announcement regarding the appropriation of profit (Gewinnverwendungsbeschluss) and the declaration of dividends for the 2018 fiscal year, as resolved by the Annual General Meeting. Since it specifically details the dividend amount per share and the payment structure, it falls under the 'Notice of Dividend Amount' category.
2019-07-08 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2018 bis zum 31.12.2018
Audit Report / Information Classification · 98% confidence The document is a 'Bericht des Aufsichtsrats' (Report of the Supervisory Board) for Biotest Aktiengesellschaft for the fiscal year 2018. In German corporate governance, the Supervisory Board report is a mandatory component of the annual reporting package, typically included within the Annual Report (10-K equivalent). Since this is a detailed report on the board's activities, oversight, and governance for the full fiscal year, it falls under the category of Annual Report/Financial Reporting documentation. FY 2018
2019-06-25 German

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.